Skip to main content
Innate Pharma logo

Innate Pharma — Investor Relations & Filings

Ticker · IPH ISIN · FR0010331421 LEI · 9695002Y8420ZB8HJE29 PA Manufacturing
Open in API
Filings indexed 1,403 across all filing types
Latest filing 2025-04-23 Capital/Financing Update
Country FR France
Listing PA IPH

About Innate Pharma

http://www.innate-pharma.com/

Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Capital/Financing Update Classification · 1% confidence The document is a press release dated April 23, 2025, announcing a restructuring of a research and license agreement between Innate Pharma and Sanofi, including the regaining of rights for a drug candidate (SAR'579/IPH6101) and a potential strategic investment by Sanofi via a capital increase. This announcement details significant corporate and financial developments, specifically related to financing/capital structure (potential investment up to 15 million euros via capital increase) and strategic business changes. While it touches upon clinical trial updates, the primary focus is the corporate transaction and financing aspect. This aligns best with the 'Capital/Financing Update' category (CAP), as the potential investment/capital increase is a central theme. It is not a full 10-K, an earnings release (ER), or a formal proxy statement (DEF 14A/PSI).
2025-04-23 French
6-K
Foreign Filer Report
2025-04-16 English
6-K
Foreign Filer Report
2025-04-16 English
Informations privilégiées / Autres communiqués
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a press release from Innate Pharma announcing proposals to be submitted to its shareholders at the upcoming Combined General Meeting (Assemblée générale mixte) scheduled for May 22, 2025. The core proposals involve transforming the company's governance structure (from a supervisory board/management board system to a single board of directors) and proposing new members for this board. This content directly relates to corporate governance structure changes and proposals put before shareholders for a vote, which aligns closely with the scope of a Proxy Solicitation & Information Statement (DEF 14A or PSI). However, since the document is explicitly about proposing changes to the board structure and composition to be voted on at the AGM, and it details the proposed composition and future roles, it strongly suggests materials intended for shareholder voting decisions. Given the options, 'Proxy Solicitation & Information Statement' (PSI) is the most fitting category for materials detailing governance proposals and board nominations ahead of a shareholder vote. It is not a full Annual Report (10-K), an Earnings Release (ER), or a Call Transcript (CT). It is an announcement regarding governance changes and board composition for a shareholder vote, making PSI the best fit over DEF 14A (which is usually remuneration focused) or AGM-R (which is usually the meeting materials themselves).
2025-04-16 French
Inside Information / Other news releases
AGM Information Classification · 1% confidence The document explicitly announces that Innate Pharma will hold its "ANNUAL GENERAL MEETING OF SHAREHOLDERS" on May 22, 2025. It details the agenda, proposed resolutions, instructions for participation, and information regarding the Notice of Meeting. This content directly relates to the materials and announcements surrounding the Annual General Meeting (AGM). Therefore, the appropriate classification is AGM Information (AGM-R). It is not a full 10-K, an Earnings Release (ER), or a proxy statement (PSI), but specifically an announcement about the AGM itself.
2025-04-16 English
Inside Information / Other news releases
Board/Management Information Classification · 1% confidence The document is an announcement dated April 16, 2025, detailing proposals to be submitted to the Annual General Meeting (AGM) on May 22, 2025. The core subject is the transformation of the corporate governance structure (from executive/supervisory board to a CEO/board of directors) and the proposed composition of the new board, including the appointment of new members and executive roles. This directly relates to the composition of the board of directors and senior management changes, which falls under the 'Board/Management Information' category (MANG). While it mentions the AGM, the primary focus is on the governance structure change and management appointments, not the voting results (DVA) or the AGM presentation itself (AGM-R). It is a formal announcement of management/governance changes.
2025-04-16 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.